Avalo Therapeutics Inc. (AVTX)
6.69
-0.62 (-8.48%)
At close: Mar 03, 2025, 3:59 PM
6.70
0.15%
After-hours: Mar 03, 2025, 04:00 PM EST
Avalo Therapeutics Balance Sheet Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Cash & Equivalents | 7.42M | 13.17M | 54.59M | 18.92M | 3.61M | 10.65M | 2.47M | 5.13M | 21.16M | 11.74M | 3.42M | 9.52M |
| Short-Term Investments | n/a | n/a | n/a | n/a | 7.63M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Long-Term Investments | n/a | 131K | 227K | 148.64K | 101.94K | 81.72K | 131.35K | 62.83K | n/a | n/a | n/a | n/a |
| Other Long-Term Assets | 131K | 131K | 1.23M | 149K | 102K | -91.24K | 131.35K | 173.00 | n/a | 117.17K | 873.85K | -56.75K |
| Receivables | 136K | 1.92M | 4.8M | 2.18M | n/a | 822.33K | 2.94M | 132.47K | n/a | n/a | n/a | n/a |
| Inventory | n/a | 20K | 38K | 3K | 21K | 1.11M | 382.15K | 11K | n/a | n/a | n/a | n/a |
| Other Current Assets | 844K | 1.3M | 2.42M | 4.91M | 1.91M | 10.15M | 4.88M | 402.36K | 460.38K | 418.64K | 714.28K | 429.96K |
| Total Current Assets | 8.39M | 16.42M | 61.84M | 26M | 17.72M | 21.93M | 10.99M | 5.66M | 21.62M | 12.16M | 4.14M | 9.95M |
| Property-Plant & Equipment | 1.97M | 2.41M | 2.69M | 1.61M | 1.45M | 586.51K | 44.61K | 43K | 35K | 38.74K | 65.99K | 56.75K |
| Goodwill & Intangibles | 10.5M | 14.41M | 14.45M | 15.99M | 16.84M | 47.65M | 31.96M | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 12.6M | 16.95M | 18.37M | 17.75M | 18.39M | 48.32M | 32.13M | 106K | 35K | 155.91K | 939.84K | 56.75K |
| Total Assets | 20.99M | 33.37M | 80.21M | 43.76M | 36.11M | 70.25M | 43.12M | 5.77M | 21.66M | 12.32M | 5.08M | 10.02M |
| Account Payables | 446K | 2.88M | 3.37M | 2.57M | 2.08M | 1.45M | 1.3M | 1.01M | 678.11K | 931.14K | 1.64M | 821.11K |
| Deferred Revenue | n/a | 88K | 16.02M | 10.88M | -155.81K | 2.03M | n/a | 942.57K | 1.89M | 975.11K | n/a | n/a |
| Short-Term Debt | 537K | 6.46M | 485K | 426K | 155.81K | n/a | n/a | 2.35M | 3.21M | 1.91M | n/a | n/a |
| Other Current Liabilities | 3.63M | 12.68M | 16.03M | 12.22M | 9.37M | 22.74M | 7.85M | 947.99K | 1.96M | 2.16M | 1.43M | 722.68K |
| Total Current Liabilities | 4.62M | 22.11M | 19.89M | 15.22M | 12.16M | 26.22M | 11.41M | 4.31M | 5.85M | 4.99M | 3.07M | 1.54M |
| Long-Term Debt | n/a | 13.49M | 32.83M | n/a | 1.11M | n/a | n/a | n/a | 2.35M | 5.31M | n/a | n/a |
| Other Long-Term Liabilities | 8.92M | 8.54M | 4.3M | 3.97M | 1.76M | 23.06M | 3.85M | 1.25M | 370.54K | 28.35M | 19.86M | n/a |
| Total Long-Term Liabilities | 9.07M | 22.17M | 37.24M | 3.97M | 2.95M | 23.13M | 3.86M | 1.25M | 8.57M | 33.65M | 19.86M | n/a |
| Total Liabilities | 13.69M | 44.28M | 57.13M | 19.19M | 15.11M | 49.34M | 15.26M | 5.56M | 8.57M | 38.65M | 22.92M | 1.54M |
| Total Debt | 537K | 19.42M | 32.83M | 426.35K | 1.27M | 15.38M | n/a | 2.35M | 5.56M | 7.21M | n/a | n/a |
| Common Stock | 1K | 9K | 113K | 75K | 44K | 40.8K | 2.69M | 9.43K | 8.65K | 650.00 | 643.00 | 18K |
| Retained Earnings | -335.13M | -303.82M | -262.17M | -177.79M | -114.29M | -98.22M | -58.17M | -70.04M | -53.56M | -43.07M | -27.02M | -13.97M |
| Comprehensive Income | n/a | n/a | n/a | -0.00 | -0.00 | n/a | 2.66M | n/a | -21.66B | -28.35M | -19.86M | n/a |
| Shareholders Equity | 7.3M | -10.91M | 23.08M | 24.56M | 21M | 20.91M | 27.86M | 207K | 13.08M | -26.33M | -17.85M | 8.48M |
| Total Investments | 131K | 131K | 227K | 148.64K | 7.63M | 81.72K | 131.35K | 62.83K | n/a | n/a | n/a | n/a |